1-4 of 4
David A. Flowers
Close
Sort by
Journal Articles

Priming with Myeloid Growth Factors Enhances CD33 Expression, Decreases P-Glycoprotein Activity, and Improves Efficacy of Gemtuzumab Ozogamicin against Acute Myeloid Leukemia (AML) Colony Forming Cells (CFC)

Roland B. Walter, MD, PhD, Sarah E. Fairchild, David A. Flowers, Tom C. Hong, Irwin D. Bernstein, MD
Journal: Blood
Blood (2008) 112 (11): 2638.
https://doi.org/10.1182/blood.V112.11.2638.2638
Published: 2008
Journal Articles

CD33 expression and P-glycoprotein–mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

Clinical Trials & Observations Brief Report
Roland B. Walter, Ted A. Gooley, Vincent H. J. van der Velden, Michael R. Loken, Jacques J. M. van Dongen, David A. Flowers, Irwin D. Bernstein, Frederick R. Appelbaum
Journal: Blood
Blood (2007) 109 (10): 4168–4170.
https://doi.org/10.1182/blood-2006-09-047399
Published: 2007
Journal Articles

Multidrug resistance protein attenuates gemtuzumab ozogamicin–induced cytotoxicity in acute myeloid leukemia cells

Roland B. Walter, Brian W. Raden, Tom C. Hong, David A. Flowers, Irwin D. Bernstein, Michael L. Linenberger
Journal: Blood
Blood (2003) 102 (4): 1466–1473.
https://doi.org/10.1182/blood-2003-02-0396
Published: 2003
Journal Articles

Loss of heterozygosity in childhood de novo acute myelogenous leukemia

David A. Sweetser, Chien-Shing Chen, Adam A. Blomberg, David A. Flowers, Patricia C. Galipeau, Michael T. Barrett, Nyla A. Heerema, Jonathan Buckley, William G. Woods, Irwin D. Bernstein, Brian J. Reid
Journal: Blood
Blood (2001) 98 (4): 1188–1194.
https://doi.org/10.1182/blood.V98.4.1188
Published: 2001